Insider Selling: Becton, Dickinson and Company (NYSE:BDX) EVP Sells 2,438 Shares of Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares in the company, valued at $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Becton, Dickinson and Company Trading Up 1.0%

Shares of NYSE BDX traded up $1.73 during midday trading on Wednesday, reaching $183.14. The company had a trading volume of 1,551,492 shares, compared to its average volume of 2,694,387. The stock has a market cap of $50.46 billion, a PE ratio of 55.16, a price-to-earnings-growth ratio of 12.66 and a beta of 0.19. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35. The firm’s fifty day moving average price is $156.55 and its 200-day moving average price is $161.69. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.84% and a net margin of 4.52%.The business had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period last year, the company earned $3.68 EPS. Becton, Dickinson and Company’s revenue for the quarter was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities research analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 126.51%.

Institutional Investors Weigh In On Becton, Dickinson and Company

Hedge funds have recently added to or reduced their stakes in the stock. Brighton Jones LLC lifted its holdings in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 877 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in Becton, Dickinson and Company by 4.4% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 627,900 shares of the medical instruments supplier’s stock valued at $122,403,000 after acquiring an additional 26,671 shares during the last quarter. Cooke & Bieler LP lifted its stake in Becton, Dickinson and Company by 27.2% in the 4th quarter. Cooke & Bieler LP now owns 1,126,471 shares of the medical instruments supplier’s stock worth $218,614,000 after purchasing an additional 240,673 shares in the last quarter. KLP Kapitalforvaltning AS boosted its holdings in shares of Becton, Dickinson and Company by 61.2% during the 4th quarter. KLP Kapitalforvaltning AS now owns 172,580 shares of the medical instruments supplier’s stock valued at $33,493,000 after purchasing an additional 65,500 shares during the last quarter. Finally, Third View Private Wealth LLC purchased a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at about $4,992,000. 86.97% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

BDX has been the topic of a number of analyst reports. Piper Sandler boosted their price objective on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Bank of America lowered their price target on Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. UBS Group initiated coverage on Becton, Dickinson and Company in a research report on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price objective on the stock. The Goldman Sachs Group dropped their price target on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research note on Wednesday, May 27th. Finally, TD Cowen boosted their price objective on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $185.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.